Uncategorized

🎭✨Valerie Taly takes the stage! Valerie Taly pitched at the Théâtre des Variétés in Paris for the Trophées de la Healtech Edition 2026, and what a memorable evening it was for the METHYS Dx team! 🤩First of all, a huge thank you to France Biotech for this wonderful evening, and kudos to Nicolas Rossignol for […]

🚀METHYS Dx signs exclusive License Agreement with CNRS Innovation for disruptive detection technology!! 🤝We are pleased to announce that METHYS Dx has signed an exclusive license agreement with CNRS Innovation covering three patent families on an ultra-sensitive and disruptive detection technology. 🔬 This technology primarily originates from collaborative work between CNRS and Université de Tokyo, […]

It has already been more than a month since our interns joined the METHYS Dx adventure, and we are delighted to have welcomed Elsa Connor, Nel Straub and Mathis Ogire to the team. Since their arrival, they have quickly integrated into our daily work and are actively contributing to various projects at the intersection of research, innovation and cancer diagnostics. Their curiosity, commitment and fresh […]

🚀 METHYS Dx is opening its capital to individuals : Our fundraising campaign is now live! We are thrilled to announce that METHYS Dx has officially opened its equity crowdfunding campaign to the public on Capital Cell! 🚀✨ We are inviting all of you to join us in revolutionizing cancer patient follow-up through innovative liquid […]

🔬 We are thrilled to announce that METHYS Dx is now a member of European Liquid Biopsy Society (ELBS) ! We are delighted to be part of this great community dedicated to advance liquid biospy research and innovation in oncology. At METHYS Dx, we develop methylation-based solutions to enable cancer monitoring using our digital PCR […]

Today marks World Cancer Day, an important moment to raise awareness, reflect, and reaffirm our collective commitment to fighting cancer. This day is a reminder of the importance of research, innovation and collaboration to improve prevention, diagnosis, patient follow-up and care. At Methys Dx, we remain committed to contributing to these efforts through our work […]

Paris, 01/12/2025. METHYS Dx, a company with pioneering liquid biopsy solutions based on methylation signatures, announced today it had entered into a distribution agreement with CliniSciences. This agreement will enable the large-scale commercialization of METHYS Dx M*Detect kits for digital PCR in RUO (Research Use Only) format across Europe, North America and North Africa. METHYS […]

Valerie Taly will give a keynote lecture at the European Digital PCR Symposium (18-19 Nov) organized by the Ghent University Digital PCR Center and coordinated by Wim Trypsteen and Ward Despiegelaere. With a cutting-edge program this symposium (followed by a workshop organised in the Digital PCR center) will be a great opportunity to discuss last […]

13/10/2025 – METHYS Dx is proud to join forces with Geeng Genetic Genius in a strategic partnership aimed at enhancing the integration of innovative technologies in diagnostic applications. Alongside Geeng, METHYS Dx brings its expertise in liquid biopsy to this shared ambition, delivering more agile, personalized, and clinically relevant diagnostic solutions for patients. A big […]

Valerie Taly will give a talk on Methylation Based Biomarkers & Digital PCR for Cancer Patient Follow-up October 1st at the Biomarkers & Precision Medicine 2025 conference in London ! Valérie will be sharing our latest insights on the follow-up of several cancers, her presentation will take place in Conference Room 4, on October 1st […]